Good news: The biotechnology industry is collapsing

 If you read the newspapers, you may not know it, but biotechnology is going through a process of collapse. According to authoritative pharmaceutical industry online Endpoints News:

The opening months of 2025 have offered no respite to the chilly biotech market of the last few years, biotech correspondent Kyle LaHucik reported this week. Despite the comeback everybody seems to want, there’s been a steady drumbeat of restructurings, pipeline cuts, layoffs and short-lived pivots. Kyle highlighted iTeos Therapeutics, once a darling of the anti-TIGIT class of biotechs, as an embodiment of the current struggles. iTeos had a clinical failure and lost a partnership with GSK this spring. It’s now shut down.

The picture is stark. Biotechnology is in a terminal existential crisis. According to Raymond James bankers who provided data to Endpoints, there were six strategic reviews launched in April alone, with 30 active strategic reviews as of 4 May. These strategic reviews are being conducted because biotechnology research is not delivering viable products. According to Stifel bankers, at least 168 biotechnology companies have negative enterprise value as of 16 May. And the dreariness follows 90 total restructurings in 2024. Fewer than five new biotechnology companies have been floated so far this year, down from 16 last year.

Biotechnology is an industry built on an exclusively materialistic paradigm of life. In fact, as everyone experiences every day, life involves a continuous interaction between consciousness and matter, mind and body, psychology and physiology, awareness and the environment. To pretend otherwise, to ignore consciousness as the prime mover of life, as myopic bio scientists continue to do so, is a fatal error and a scientific dead end.

As a result, biotechnology is an industry built on false advertising dreams and the same kind of financial thinking that leads millions of people, who are doomed to disappointment, to buy lottery tickets every week.

Five years ago, a door was opened which allowed failed covid “vaccine” and treatment products onto the market without long-term testing. This was not just “on the market,” it was forced on unwilling populations as a modern-day exponential expansion of Mengele-style medical research. The result has been a public health disaster, as we all now know (except for some extreme dreamers who keep their faith and belief in a biotechnology future). Floundering in a sea of adverse events, they are trying to save their misguided and twisted paradigm of life by pretending success is just around the corner. Vinay Prasad, Trump’s head of the Centre for Biologics Evaluation and Research (“CBER”), which regulates biotechnology, has promised “to ‘rapidly’ push even small advances for rare disease drugs.”...<<<Read More>>>....

Because of the “success” of covid, New Zealand has introduced a Gene Technology Bill

 The dream of biotechnology, which promised a new age of health and human achievement, has become a nightmare, with its success stories being largely myths and its main beneficiaries being transnational corporations.

The covid-19 pandemic is viewed as the greatest success story of biotechnology, but it has also highlighted the risks and dangers of the industry, with the development of a deadly disease and a vaccine that has harmed many people.

This covid “success” has led to the New Zealand government introducing the Gene Technology Bill, which contains permissive legislation that favours transnational corporations and ignores public safety and environmental concerns.

The bill’s introduction is believed to be driven by trade negotiations with the US, which wants New Zealand to deregulate biotechnology to pave the way for similar deregulation in Europe.

Meanwhile, Australia already has a Gene Technology Regulator who has announced a project that is proposing to make gene-altered versions of the flu and then test out various genetic drugs and/or vaccines on human volunteers.

If you ask Google what are the biotechnology success stories, it comes up with slim pickings.

First up is a list of patented genetically engineered crops like cotton, soya and corn. These types are paired with proprietary pesticide products.

A March 2023 report from the USDA Agricultural Marketing Service (“AMS”) says a consolidation trend within the agricultural seed industry began when the first genetically engineered traits were introduced to the market in the early 1990s. Since then, more than 200 US seed companies have been acquired or gone out of business. The result is a concentration of market share among four seed companies.

A June 2023 report by the USDA Economic Research Service (“ERS”) found that when combined, AgReliant, Bayer, Corteva and Syngenta accounted for 83% of corn seed sales and 78% of soyabean seed sales in the United States from 2018 to 2020. The trend is continuing, Bayer has just announced the consolidation of a further 10 regional seed brands in 2025.

This so-called success story of biotechnology is not about more nutritious strains, increased yields, etc., these largely remain the stuff of myth. It is about the profits of transnational corporations that control a concentration of intellectual property (“IP”) in the form of patented genetics and traits. This has left farmers trapped in an unsustainable cycle of heightened input costs and depressed commodity prices. This is not a route for New Zealand farming to travel. Much of the allure of New Zealand produce is our pristine shores and clean green image. The genetically engineered (“GE”) route leads to corporate slavery, trade barriers, public rejection and rock bottom prices.

Next up on Google is a list of biotech startups that promise a lot, but do they deliver...<<<Read More>>>...